Self-screen

Executive Summary

Self-screen is a private Dutch diagnostics company focused on cervical cancer screening and prevention. Founded in 2017, the company has developed two clinically validated assays currently on the market, with an aim to transition toward all-molecular screening to enhance objectivity, reproducibility, and high-throughput capabilities. Operating out of Amsterdam, Self-screen has not publicly disclosed funding rounds or valuation, and remains in early commercialization stages. The company targets a growing global cervical cancer screening market, but faces significant competition from established diagnostic firms. Given its private status and lack of recent public updates, Self-screen’s near-term trajectory is uncertain; however, its focus on molecular screening positions it for potential growth if it secures regulatory approvals or strategic partnerships.

Upcoming Catalysts (preview)

• TBDRegulatory approval for expanded assay panel (e.g., CE-IVDR or FDA 510(k))30% success
• TBDStrategic distribution partnership with a global diagnostics company25% success
• TBDPublication of key clinical validation study in a peer-reviewed journal40% success